Notis McConarty Edward decreased its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 5.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,257 shares of the medical research company’s stock after selling 710 shares during the period. Amgen comprises about 1.3% of Notis McConarty Edward’s portfolio, making the stock its 25th largest holding. Notis McConarty Edward’s holdings in Amgen were worth $2,305,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the business. FMR LLC increased its stake in Amgen by 4.8% during the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after purchasing an additional 2,587,041 shares during the last quarter. Vanguard Group Inc. increased its stake in Amgen by 0.9% during the second quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock valued at $8,981,266,000 after purchasing an additional 489,720 shares during the last quarter. BlackRock Inc. increased its stake in Amgen by 1.9% during the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after purchasing an additional 909,689 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Amgen by 1.7% during the third quarter. Bank of New York Mellon Corp now owns 8,166,002 shares of the medical research company’s stock valued at $1,522,551,000 after purchasing an additional 140,117 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in Amgen by 12.9% during the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after purchasing an additional 806,119 shares during the last quarter. Hedge funds and other institutional investors own 79.61% of the company’s stock.
In related news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total value of $265,624.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.19% of the company’s stock.
Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $188.24 on Friday. The firm has a market cap of $135,638.59, a PE ratio of 73.25, a P/E/G ratio of 2.31 and a beta of 1.37. Amgen, Inc. has a 1-year low of $152.16 and a 1-year high of $201.23. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the consensus estimate of $3.03 by ($0.14). The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the previous year, the company earned $2.89 EPS. analysts forecast that Amgen, Inc. will post 13.25 EPS for the current fiscal year.
Amgen announced that its Board of Directors has authorized a share buyback plan on Thursday, February 1st that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its shares are undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be issued a $1.32 dividend. This represents a $5.28 annualized dividend and a yield of 2.80%. The ex-dividend date is Wednesday, May 16th. Amgen’s payout ratio is currently 205.45%.
AMGN has been the subject of several recent research reports. BidaskClub upgraded shares of Amgen from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 2nd. Morgan Stanley lowered their target price on shares of Amgen from $204.00 to $196.00 and set an “overweight” rating for the company in a research note on Friday, February 2nd. Vetr upgraded shares of Amgen from a “sell” rating to a “hold” rating and set a $181.60 target price for the company in a research note on Tuesday, February 27th. Oppenheimer reissued a “buy” rating and set a $205.00 price target on shares of Amgen in a report on Tuesday, January 30th. Finally, Piper Jaffray Companies reissued a “buy” rating on shares of Amgen in a report on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Amgen currently has an average rating of “Hold” and a consensus target price of $191.72.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2018/03/18/amgen-inc-amgn-shares-sold-by-notis-mcconarty-edward.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.